N
Neeraj Jain
Researcher at University of Texas MD Anderson Cancer Center
Publications - 66
Citations - 1525
Neeraj Jain is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Mantle cell lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 16, co-authored 58 publications receiving 838 citations. Previous affiliations of Neeraj Jain include Nanyang Technological University & All India Institute of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.
Qing Deng,Guangchun Han,Nahum Puebla-Osorio,Man Chun John Ma,Paolo Strati,Beth Chasen,Enyu Dai,Minghao Dang,Neeraj Jain,Haopeng Yang,Yuanxin Wang,Shaojun Zhang,Ruiping Wang,Runzhe Chen,Jordan Showell,Sreejoyee Ghosh,Sridevi Patchva,Qi Zhang,Ryan Sun,Frederick B. Hagemeister,Luis Fayad,Felipe Samaniego,Hans C. Lee,Loretta J. Nastoupil,Nathan Fowler,R. Eric Davis,Jason R. Westin,Sattva S. Neelapu,Linghua Wang,Michael R. Green +29 more
TL;DR: Heterogeneity in the cellular and molecular features ofCAR T cell infusion products contributes to variation in efficacy and toxicity after axi-cel therapy in LBCL, and that day 7 molecular response might serve as an early predictor of CAR T cell efficacy.
Journal ArticleDOI
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Rohitash Yadav,Jitendra Kumar Chaudhary,Neeraj Jain,Pankaj Kumar Chaudhary,Supriya Khanra,Puneet Dhamija,Ambika Sharma,Ashish Kumar,Shailendra Handu +8 more
TL;DR: In this paper, the authors focused on genomic organization, structural and non-structural protein components, and potential prospective molecular targets for development of therapeutic drugs, convalescent plasm therapy, and a myriad of potential vaccines to tackle SARS-CoV-2 infection.
Journal ArticleDOI
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
Baohua Sun,Warren Fiskus,Yimin Qian,Kimal Rajapakshe,Kanak Raina,Kevin Coleman,Andrew P. Crew,Angela Shen,Dyana T. Saenz,Christopher P. Mill,Agnieszka J Nowak,Neeraj Jain,Li Zhang,Michael Wang,Joseph D. Khoury,Cristian Coarfa,Craig M. Crews,Kapil N. Bhalla +17 more
TL;DR: Promising and superior preclinical activity of BET-PROTAC than BETi is highlighted, requiring further in vivo evaluation of BET (proteolysis-targeting chimera) as a therapy for ibrutinib-sensitive or -resistant MCL.
Journal ArticleDOI
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Patrizia Mondello,Saber Tadros,Matt Teater,Lorena Fontan,Aaron Y. Chang,Neeraj Jain,Huan Yang,Shailbala Singh,Hsia-Yuan Ying,Chi-Shuen Chu,Man Chun John Ma,Eneda Toska,Stefan Alig,Matthew Durant,E. De Stanchina,Sreejoyee Ghosh,Anja Mottok,Loretta J. Nastoupil,Sattva S. Neelapu,Oliver Weigert,Giorgio Inghirami,Jose Baselga Baselga,Anas Younes,Cassian Yee,Ahmet Dogan,David A. Scheinberg,Robert G. Roeder,Ari Melnick,Michael R. Green +28 more
TL;DR: HAC3 inhibition represents a novel mechanism-based immune-epigenetic therapy for CREBBP mutant lymphomas and restored the ability of tumor infiltrating lymphocytes to kill DLBCL cells in an MHC class I and II dependent manner.
Journal ArticleDOI
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Kayo Kondo,Hila Shaim,Philip A. Thompson,Jan A. Burger,M. Keating,Zeev Estrov,David Harris,Ekaterina Kim,A. Ferrajoli,May Daher,Rafet Basar,Muharrem Muftuoglu,Nobuhiko Imahashi,Abdullah Alsuliman,Catherine Sobieski,Elif Gokdemir,William G. Wierda,Neeraj Jain,Enli Liu,Elizabeth J. Shpall,Katy Rezvani +20 more
TL;DR: Findings provide a mechanistic basis for immunomodulation by ibrutinib through inhibition of the STAT3 pathway, critical in inducing and sustaining tumor immune tolerance.